CEO of the British-Swedish pharma giant AstraZeneca, Pascal Soriot said that the vaccine developed by the University of Oxford will protect 95 percent of the patients who receive it. He also said that the vaccine “should” be effective against the new variant of the virus.
AstraZeneca has partnered with the Serum Institue of India for the rollout of the COVID-19 vaccine. It is believed by experts that this vaccine could be the first one to get emergency use approval from the Drug Controller General of India (DGCI).
COVID-19 vaccine by Oxford to protect 95% of patients, says AstraZeneca CEO
